MyFinsight
Home
About
Contact
bbio: the balance sheet
Income Statement
|
Cash Flow
|
Balance Sheet
For the quarter ending 2025-09-30, BBIO has $998,250K in assets.
Balance Sheets Overview
00
No enough data to generate the overview
Buy me a coffee
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Quarterly
123
Balance Sheets
2025-09-30
2025-06-30
Total assets
998,250
1,080,190
Total liabilities, redeemable convertible noncontrolling interests and stockholders deficit
998,250
1,080,190
Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Page 1
Subscribe for Financial Insights
Time Plot
Show the time plot by selecting a row from the table.
Balance Sheets
Prepaid expenses and
other current assets
$52,395K
Inventories
$24,527K
Accounts receivable, net
$116,518K
Marketable securities
$2,991K
Cash and cash
equivalents
$642,951K
Other assets
$25,522K
Intangible assets, net
$28,795K
Operating lease
right-of-use assets
$6,553K
Property and equipment,
net
$5,830K
Investment in
nonconsolidated entities
$92,168K
Total current assets
$839,382K
Accumulated deficit
-$3,628,331K
Treasury stock, at cost
7,597,172 shares as of...
$323,276K
Total assets
$998,250K
Total bridgebio
stockholders deficit
-$1,933,070K
Accumulated other
comprehensive income
$2K
Additional paid-in capital
$2,018,335K
Common stock, 0.001 par
value 500,000,000...
$200K
Total liabilities,
redeemable convertible...
$998,250K
Total stockholders
deficit
-$1,922,752K
Noncontrolling interests
$10,318K
Redeemable convertible
noncontrolling interests
$23K
Total liabilities
$2,920,979K
Other long-term
liabilities
$679K
Deferred revenue, net of
current portion
$13,131K
Operating lease
liabilities, net of current...
$3,427K
Deferred royalty
obligations, net
$836,126K
2031 notes, 2029
notes, 2027 notes, and...
$546,549K
2031 notes, 2029
notes, 2027 notes, and...
$740,380K
2031 notes, 2029
notes, 2027 notes, and...
$564,087K
Total current
liabilities
$216,600K
Unamortized debt discount
and issuance costs
$61,962K
Fair value of
embedded derivative...
$30,029K
Carrying value of
deferred royalty...
$868,059K
Other current
liabilities
$92,743K
Deferred revenue,
current portion
$9,087K
Operating lease
liabilities, current portion
$5,294K
Accrued research and
development liabilities
$34,619K
Accrued compensation
and benefits
$56,155K
Accounts payable
$18,702K
Funding Agreement
$30,029K
Subscribe for Financial Insights
BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO)